EMA Requests Immediate Recall of MS Drug Daclizumab (Zinbryta)

Just days after the company announced voluntary withdrawal of the drug, the EMA recommends immediate suspension and recall of daclizumab in multiple sclerosis.
News Alerts

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply